Clinical Core B

临床核心B

• 批准号: 10452559
• 负责人: DANIEL WEINTRAUB
• 金额: $ 65.21万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10452559
• 关键词: Address; Aging; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Area; Autopsy; Bioinformatics; Biological Markers; Biometry; Blood; Blood Banks; Brain; Centers of Research Excellence; Charge; Clinical; Clinical Research; Clinical assessments; Cognition; Collaborations; Common Data Element; Communities; Community Outreach; Consensus; Consent; DNA; Data; Data Collection; Databases; Dementia; Dementia with Lewy Bodies; Diagnosis; Diagnostic; Disease; Education; Education and Outreach; Faculty; Family; Foundations; General Population; Genetic; Goals; Grant; Health Personnel; Heterogeneity; Interdisciplinary Study; International; Lewy Bodies; Lewy Body Dementia; Lewy Body Disease; Lewy neurites; Link; Magnetic Resonance Imaging; Mediating; Medical; Medical center; Motor; Movement Disorders; Multicenter Studies; National Institute of Neurological Disorders and Stroke; Neurodegenerative Disorders; Neuropsychological Tests; Parkinson Disease; Parkinson' s Dementia; Participant; Pathologic; Pathology; Patients; Pennsylvania; Persons; Philadelphia; Physicians; Process; RNA; Research; Research Personnel; Sampling; Source; Spinal Puncture; Tissue Banks; Tissues; Training; Training and Education; Translational Research; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; Visit; Work; alpha synuclein; beta amyloid pathology; biomedical referral center; brain tissue; clinical biomarkers; clinical center; clinical diagnosis; cohort; data management; data sharing; in vivo; medical schools; mild cognitive impairment; mixed dementia; neuroimaging; neuropathology; next generation; programs; progressive neurodegeneration; recruit; tau Proteins; translational scientist; underserved minority

Project Summary / Abstract Core B (Clinical Core) of this NIA U19 Center at the University of Pennsylvania (Penn) Perelman School of Medicine will be crucial to accomplishing the goals of all Projects and other Cores of this multidisciplinary research program. The Penn U19 Center focuses on priorities that address Alzheimer's disease (AD) and related dementias (ADRD) in topic areas of multiple etiology dementias, such as Lewy body (LB) disorders (LBD), including dementia with Lewy bodies (DLB) and Parkinson's disease (PD) dementia (PDD). Among ADRD, AD with abundant LB co-pathology is the most common subtype of AD. Hence, AD with LB and Lewy neurite (LN) alpha-synuclein (aSyn) pathologies (AD+aSyn), PDD and DLB together represent the most common forms of aging-related dementias. The overall goals of this new Penn ADRD U19 Center are to elucidate mechanisms of pathological aSyn-mediated progressive neurodegeneration in AD+aSyn versus pure AD (AD-aSyn), and also compared with LBD, as a function of aging and the heterogeneous accumulations of aSyn, tau and amyloid β (Aβ) pathologies that influence different and variable clinical manifestations of these disorders. The aims for Core B are to: (1) recruit, assess and retain research participants with LBD for U19 Projects I-IV; (2) collaborate with Core C for biomarker/biofluid and tissue collection from existing and new Core B LBD participants, and to assess them longitudinally antemortem for as long as possible to optimize clinical-pathological correlations; (3) collaborate with Core A to educate the medical community and general public on LBD and related disorders, and to train the next generation of PD clinical and translational researchers; and (4) collaborate with Core D to contribute high-quality clinical and biomarker data to the Penn Integrated NeuroDegenerative Disease Database (INDD) and facilitate sharing of clinical and biomarker data within and outside of Penn with new and longstanding internal, national and international collaborators.

项目概要/摘要 宾夕法尼亚大学 (Penn) 佩雷尔曼学院 NIA U19 中心的核心 B（临床核心） 医学对于实现这个多学科的所有项目和其他核心目标至关重要 研究计划。宾夕法尼亚大学 U19 中心重点关注解决阿尔茨海默病 (AD) 和 多病因痴呆主题领域的相关痴呆 (ADRD)，例如路易体 (LB) 疾病 （LBD），包括路易体痴呆（DLB）和帕金森病（PD）痴呆（PDD）。之中 ADRD、AD 与丰富的 LB 共同病理是 AD 最常见的亚型。因此，AD 与 LB 和 Lewy 神经突 (LN) α-突触核蛋白 (aSyn) 病理学 (AD+aSyn)、PDD 和 DLB 共同代表了最 与衰老相关的痴呆症的常见形式。新宾夕法尼亚 ADRD U19 中心的总体目标是 阐明 AD+aSyn 与纯 AD 中病理性 aSyn 介导的进行性神经变性的机制 AD (AD-aSyn)，并与 LBD 进行比较，作为衰老和异质积累的函数 aSyn、tau 和淀粉样蛋白 β (Aβ) 病理学影响这些疾病的不同且可变的临床表现 失调。核心 B 的目标是：(1) 招募、评估和保留 U19 的 LBD 研究参与者 项目一至四； (2) 与 Core C 合作，从现有和新的生物标志物/生物流体和组织收集中 核心 B LBD 参与者，并在生前对其进行尽可能长时间的纵向评估以优化 临床病理相关性； (3) 与核心 A 合作，教育医学界和公众 公众了解 LBD 和相关疾病，并培训下一代 PD 临床和转化 研究人员； (4) 与 Core D 合作，向 Penn 贡献高质量的临床和生物标志物数据 综合神经退行性疾病数据库 (INDD) 并促进临床和生物标志物数据的共享 在宾夕法尼亚大学内外与新的和长期的内部、国家和国际合作者合作。